Coya Therapeutics in-licenses Dr. Reddy's Abatacept biosimilar for COYA 302; $350K upfront, up to $22.7M milestones

Coya Therapeutics, Inc.

Exclusive License and Supply Agreement with Dr. Reddy's for Abatacept biosimilar, effective April 1, 2023.
Upfront payment of $350,000; potential development, regulatory and sales milestones up to ~$22.7 million.
COYA 302 combines Coya's low-dose IL-2 (COYA 301) with the biosimilar for neurodegenerative diseases.
Coya responsible for development; Dr. Reddy's for manufacture and supply of biosimilar.
Agreement covers U.S., Canada, Mexico, South America, EU, UK, Japan; cross-license for COYA 301 in other territories.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Coya Therapeutics, Inc. entered into License Agreement with Dr. Reddy's Laboratories Limited valued at $350,000 (effective 2023-03-16).

Action: entry
Agreement: license
Counterparty: Dr. Reddy's Laboratories Limited
Value: $350,000
Effective: 2023-03-16

Exact text from the filing

On March16, 2023, Coya Therapeutics, Inc. (the “Company”) entered into an exclusive License and Supply Agreement (the “License Agreement”) with Dr. Reddy’s Laboratories Limited (“DRL”).

View on SEC.gov

629 material agreements filed in the last 30 days. Browse all material agreements →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-076795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.